Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers

Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers

Abstract Background Chronic migraine is a complex clinical condition often undertreated. Onabotulinumtoxin A (OBT-A) was approved in Italy in 2013 for symptom relief in patients with chronic migraine who have failed, or do not tolerate, oral prophylactic treatments. However, the impact of OBT-A in c...

Full description

Bibliographic Details
Main Authors: Cristina Tassorelli, Marco Aguggia, Marina De Tommaso, Pierangelo Geppetti, Licia Grazzi, Luigi Alberto Pini, Paola Sarchielli, Gioacchino Tedeschi, Paolo Martelletti, Pietro Cortelli
Format: Article
Language:English
Published: BMC 2017-06-01
Series:The Journal of Headache and Pain
Subjects:
Botox
Chronic migraine
Headache
Migraine prophylaxis
Onabotulinumtoxin A
Online Access:http://link.springer.com/article/10.1186/s10194-017-0773-7

Internet

http://link.springer.com/article/10.1186/s10194-017-0773-7

Similar Items